Injectsense announces first human implant of ultraminiature IOP sensor

News
Article

Injectsense's future plans for the sensor are to fine-tune its delivery tool and incorporate a microbattery into the sensor.

IOP detecting sensor and its applicator Image credit: Injectsense

Image credit: Injectsense

Digital health company Injectsense announced that it has successfully completed the first human implant and wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation.1 The implant procedure was performed during the IOP-Connect system study by Juan Mura, MD, of the Centro de la Vision in Santiago, Chile, according to a news release.

"From a physician's perspective, this is a major step toward understanding IOP fluctuations and providing more effective glaucoma treatment," said Mura in the release. "It's extremely exciting to have a direct path to an implantable sensor that will provide autonomous measurement 24/7."

Injectsense now plans on fine-tuning the delivery tool for the sensor and to incorporate the Injectpower SAS solid-state microbattery into the sensor. This microbattery will allow for autonomous and continuous measurement of IOP from inside the eye, according to the release. The final product platform will then use smart glasses work by patients for a few minutes each week in order to wirelessly recharge the sensor and uploaded sensor-stored data to a smart phone and cloud platform.1

"Although safety is the primary focus of this study, we are also informing our product design to meet the expectations of ophthalmologists across the globe," said Ariel Cao, President/CEO of Injectsense. "We expect these sensors to be easily delivered in the doctor's office."

In November 2023, Injectsense announced that it secured $9.4 million in funding with sister company Injectpower to bring the implantable device into production.2

References:
  1. Injectsense completes first human implantation of its ultraminiaturized intraocular pressure sensor. PR Newswire. News release. August 27, 2024. Accessed August 28, 2024. https://www.prnewswire.com/news-releases/injectsense-completes-first-human-implantation-of-its-ultraminiaturized-intraocular-pressure-sensor-302231827.html
  2. Injectsense and solid-state microbattery partner Injectpower secure $9.4 million for implantable device supply chain and support of clinical studies. Injectsense. News release. November 15, 2023. Accessed August 28, 2024. https://www.injectsense.com/1-7m-sbir-grant
Recent Videos
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.
Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.
Ashley Mills, The Vision Council CEO, outlines new additions to the show that are unveiling what is to come in terms of fashion, technology, and patient care.
Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.
Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).
Danica Marrelli, OD, FAAO, at Glaucoma 360 discussing visual field testing for patients with glaucoma
Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.
© 2025 MJH Life Sciences

All rights reserved.